Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2008

View Archived Issues

LOR-253 induces cancer cell cycle arrest in preclinical studies

CK2 protein kinase inhibitor shows antitumor activity in preclinical studies

Novartis rounds up Q1 developments

DEBIO-025 enhances antiviral effect of pegylated interferon alpha-2a in HCV patients

PF-03732010 active in vivo against P-cadherin-expressing cancers

Small-molecule inhibitors of Cdc7 kinase developed at Nerviano Medical Sciences

Progen reports synthesis of novel heparan sulfate mimetics

Alexza completes enrollment in phase IIa AZ-002 trial in panic disorder

Cleveland BioLabs presents update on the company's 2008 activities

ImmuneRegen to supply adjuvant to DynPort for Venezuelan equine encephalitis vaccine

Critical Therapeutics signs merger agreement with Cornerstone BioPharma

Accentia reports results from pivotal phase III trial of SinuNase for chronic sinusitis

3M and Infectious Disease Research Institute collaborate on vaccine adjuvants

Sepracor acquires Oryx and expands commercial operations into Canada

Sepracor and Arrow sign agreement to enhance ciclesonide and Brovana

Discovery Labs receives FDA approvable letter for Surfaxin

Oncothyreon files IND with the FDA for PX-866 for advanced cancers

Pro-Pharmaceuticals updates NDA filing plan for Davanat

AstraZeneca files marketing application for Iressa in Europe

Mologen receives approval for phase I MGN-1703 clinical study in cancer

Renovis stockholders approve adoption of the merger agreement with Evotec

New agents for treating neurological disorders disclosed in recent patent literature

Novel antithrombotic agents reported in recent patents

Recent Synta patent reports novel immunosuppressant agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...